MAPT and Alzheimer disease: Although there were technical limitations that affected the end-point interpretations of the first phase 2/3 multisite randomized double-blind clinical trial, their results suggested an advantage in the AD Assessment Scale, improved Aβ42/40 ratios, and improved Aβ42/total tau protein in the insulin group [78].